Background：Vorsetuzumab mafodotin, also known as SGN-75, is a novel antibody conjugated with a cytotoxic molecule, auristatin analogue monomethyl auristatin phenylalanine MMAF. The antibody part of vorsetuzumab mafodotin is a monoclonal antibody targeting CD70, a member of CD70 tumor necrosis factor TNF superfamily. Vorsetuzumab mafodotin, developed by Seattle Genetics, has been used in the clinical treatment of Non-Hodgkin's lymphoma and renal cancer. This drug has completed a phase I clinical study in renal cell carcinoma but was discontinued in 2013. There were no reports specifying the reasons for the cessation of development. In 2014, SG had planned to reopen clinical studies related to vorsetuzumab mafodotin.
